7/31/2018

Flurbiprofen Sodium Ophthalmic Solution

Products Affected - Description

- Flurbiprofen sodium ophthalmic solution, Valeant, 0.03%, 2.5 mL bottle, NDC 24208-0314-25

Reason for the Shortage

- Allergan discontinued Ocufen ophthalmic solution in February 2017.
- Valeant discontinued flurbiprofen sodium in early-2018.

Available Products

- Flurbiprofen sodium ophthalmic solution, Amici, 0.03%, 2.5 mL bottle, NDC 69292-0722-25

Estimated Resupply Dates

- Amici has flurbiprofen ophthalmic solution available.

Updated

Updated July 31, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. Created August 16, 2017 by Benjamin Witt, PharmD, BCPS, Drug Information Specialist. Copyright 2018, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.